Founded December 2025 · Seoul, Korea

Targeting the
Impossible

TAREXIS discovers novel First-in-Class anticancer targets through real-world patient data — bridging the translational gap with Tx-Finder™ and Tx-Verifier™.

FIC Antibody-based Anticancer Therapeutics  ·  Real-World Evidence Driven Discovery Platform
Explore Platform View Pipeline
6+
FIC Programs
$58B
NSCLC Market 2028E
3R
Discovery Framework
2
Global Partners
Scroll
About TAREXIS

Creating the
New Axis in Oncology

TAREXIS is a biotech developing innovative therapeutics through novel target discovery. We focus on patients with limited treatment options — those ineligible for targeted therapies and immunotherapies.

We combine real-world patient data, multi-omics analytics, and patient-derived organoid validation to build a high-confidence First-in-Class pipeline across NSCLC, CRC, and PDAC.

Our approach bridges the translational gap: 90% of drugs entering Phase 1 fail. The 3R Framework ensures every target decision is anchored in real-world evidence — before entering expensive clinical development.

90%

Phase 1 failure rate we're engineering around

~12mo

Target discovery to PDO validation

FIC

All pipeline assets, no same-target ADC competition

🇨🇳 Partner B (China) — TX-101 ~ TX-103
🇫🇷 Partner M (France) — TX-104
Valley of Death — Translational Gap

The Translational Gap ("Valley of Death") — bench-to-bedside translation fails for 75–90% of preclinical results. TAREXIS's 3R Framework is designed to bridge this gap.

Development Strategy

The 3R Framework

We advance drug development on the 3R framework — ensuring every target reflects real unmet medical need combined with high drug potential and commercial viability.

RWU

Real-World Unmet Needs

Needed in real clinical practice and the market?

  • KOL & clinician interviews
  • Standard-of-care gap analysis
  • Resistance & relapse pattern tracking
  • Patient-population prevalence quantification
RWD

Real-World Data

Expressed in real patients?

  • RNA-seq · WES · WGS
  • Global proteomics
  • Clinical-outcome databases
  • Biomarker profiles
RWS

Real-World Samples

Effective in real patients?

  • Patient-derived organoids (PDO)
  • Lung & colorectal PDO banks (built)
  • Breast & glioblastoma (planned)
  • In-vivo PDX animal model validation

RWU ∩ RWD = Market Relevance  ·  RWD ∩ RWS = Clinical & Functional PoC  ·  RWU ∩ RWS = Clinical Translation

→ CLINICAL SUCCESS ZONE = RWU ∩ RWD ∩ RWS

Core Technology

Proprietary Discovery Platforms

Two integrated platforms systematically narrow down high-confidence targets and pre-validate clinical performance — before IND-enabling studies begin.

🔍  Tx-Finder™

Autonomous Big-Data
Analytics Engine

Real-World Patient Data → FIC Target Discovery

A 4-step novel-target scoring system integrating RWU and RWD to auto-prioritize high-confidence FIC candidates from 10,000+ starting points. Integrates AlphaFold DB, HPA, GTEx, ClinicalTrials, and in-house omics.

Auto-prioritize best targets from 10,000+ candidates
Multi-omics integration & algorithmic scoring
Multi-dimensional: druggability + market attractiveness
Surface expression, receptor identity, safety profile

4-Step Candidate Filtering Process

Tx-Finder 4-Step Candidate Filtering Process
Tx-Finder™ Dashboard
Tx-Finder dashboard screenshot
🧫  Tx-Verifier™

Patient-Derived Organoid
Validation Platform

"Clinical Trials in a Dish"

Early efficacy validation using PDOs cultured directly from real patient tumor tissue. Captures tumor heterogeneity to pre-validate clinical performance before IND-enabling studies — minimizing late-stage failure risk.

PDOs from LUAD · LSCC · CRC patient-derived clinical network
Fail-gate strategy: eliminate poor candidates early
Responder profiling & classification
PDO xenograft → in-vivo PDX animal model validation
PDO microscopy 1 PDO microscopy 2 PDO microscopy 3

Patient-derived organoids (PDO) — real tumor tissue from TAREXIS's PDO biobank

Tx-Verifier™ · CBioPortal DB
Tx-Verifier PDO Biobank — CBioPortal-based Internal DB
Pipeline

FIC Antibody Pipeline

All assets are First-in-Class with no competing same-target ADC programs — targeting patients ineligible for existing therapies across multiple solid tumor indications.

Program Class Indication Modality Stage Partner
▸ Novel Target Pipeline
TX-101 FIC LUAD · LSCC ADC/BsADC
Discovery
 Partner B (China)
TX-102 FIC LUAD · LSCC ADC/BsADC
Discovery
 Partner B (China)
TX-103 FIC LSCC ADC/BsADC
Discovery
 Partner B (China)
TX-104 FIC LUAD · LSCC ADC/BsAb/BsADC
Discovery
 Partner M (France)
TX-201 FIC CRC ADC
Discovery
 —
TX-301 FIC PDAC ADC
Discovery
 —
▸ Bispecific Antibody Platform
TX-BSU FIC Universal BsAb/BsADC
Discovery
 —

LUAD: Lung Adenocarcinoma · LSCC: Lung Squamous Cell Carcinoma · CRC: Colorectal Cancer · PDAC: Pancreatic Ductal Adenocarcinoma

Why TAREXIS

Built to Succeed
Where Others Fail

3R Framework + Tx-Finder™ + Tx-Verifier™ = higher clinical success probability, faster development, and stronger commercial outcomes.

🎯

Maximize Clinical Success Probability

Unmet need → target → patient-derived sample validation. 3R Framework achieves higher clinical hit rate.

⚡

Speed & Efficacy

Target discovery → PDO validation in ~12 months. Real-time analytics + PDO-based early PoC.

📈

Maximize Value Creation

Weighs efficacy, safety, drug value, and market potential jointly at discovery — higher L/O probability.

🔄

Scalability Across Modalities

Applies across ADC, BsAb, TCE, and PDC. Modality fit pre-screened: 1 target → multiple modalities.

Market Opportunity

Sustained Growth +
Defined Unmet Population

The global NSCLC market is on a 9% CAGR trajectory with a large patient population still unserved by current targeted and immune therapies.

Global NSCLC Market (2028E)

$58.2B

From $34.8B in 2023 — CAGR 9%. ~18% of total oncology market.

Source: Evaluate Pharma 2024

Cold Tumor / IO Non-Responders

~70%

Of total NSCLC are cold tumors ineligible for immunotherapy. LSCC: 95.5% WOT. LUAD: 55% WOT.

Massive underserved patient population

ADC Analog Peak Sales Benchmark

$1B+

Enhertu ($6.5B), Trodelvy ($2.8B), Datroway ($1.5B) validate FIC ADC value in NSCLC.

Analyst consensus 2028E

Contact

Let's Build the
Future of Oncology

Interested in partnership, co-development, or licensing? We welcome conversations with investors, pharma partners, and research collaborators.

📧
📍
Location
Seoul, Republic of Korea
🤝
Partnerships
Co-licensing available · BD inquiries welcome

Send an Inquiry

Tell us about your interest and we'll be in touch.